Recent advances in the pharmacogenetics of clopidogrel

  title={Recent advances in the pharmacogenetics of clopidogrel},
  author={Thomas Cuisset and Pierre Emmanuel Morange and Marie-Christine Alessi},
  journal={Human Genetics},
Clopidogrel has been used to prevent recurrent ischemic events after acute coronary syndrome and/or coronary stent implantation. An impaired platelet response to this drug (residual high platelet reactivity) has been identified as a risk factor for recurrent ischemic events. The platelet response to clopidogrel is highly heritable (73%) suggesting a substantial genetic component. Two sequential cytochrome P450-dependent oxidative steps are required to convert clopidogrel to its active… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS